Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 30 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Dynamic Changes in Apolipoproteins During Anthracycline Therapy: An Exploratory Study of Potential Biomarkers of Cardiotoxicity in Breast Cancer Patients

  • Beata Puton1
  • Agata Makówka1
  • Anna Borowiec2
  • Patrycja Ozdowska3
  • Agnieszka Maria Żebrowska2,4
  • Maciej Skrzypczak5
  • Beata Kotowicz1
5 affiliations
  1. 1Cancer Biomarkers and Cytokines Laboratory Unit, Department of Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena Str. 5, 02-781 Warsaw, Poland
  2. 2Non-Commercial Clinical Research Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena Str. 5, 02-781 Warsaw, Poland
  3. 3Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena Str. 5, 02-781 Warsaw, Poland
  4. 4Unit for Screening Studies in Inherited Cardiovascular Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, 04-628 Warsaw, Poland
  5. 5Department of Gynecology, Medical University of Lublin, 20-954 Lublin, Poland
Open at sourceDOICite

Abstract

Background/Objectives: Cancer therapy-related cardiac dysfunction (CTRCD) is a clinically important complication of anthracycline-based chemotherapy, and early identification of patients at increased risk remains challenging. Apolipoproteins involved in lipid metabolism and inflammatory pathways may reflect cardiovascular alterations induced by anticancer treatment. This study aimed to evaluate changes in selected apolipoproteins and C-reactive protein (CRP) during anthracycline therapy and to assess their association with the development of CTRCD in patients with breast cancer. Methods: This prospective study included 54 patients with breast cancer treated with anthracycline-based chemotherapy at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Plasma concentrations of apolipoproteins A1, A2, B, C1, C3, D, E, H, and J, as well as CRP, were measured using an xMAP multiplex assay at baseline, after completion of chemotherapy, and approximately 6 months after treatment. Cardiac biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP, were also assessed. CTRCD was diagnosed based on standard clinical and echocardiographic criteria. Results: Anthracycline therapy significantly affected the apolipoprotein profile, with decreased concentrations of apolipoproteins A1, A2, B, C1, E, H, and J, and increased concentrations of apolipoproteins C3 (ApoC3) and D and CRP during follow-up (all p < 0.001). Patients with CTRCD showed higher concentrations of selected apolipoproteins, particularly apolipoproteins C3, E (ApoE) and A2. The change in ApoC3 concentration from baseline to 6 months demonstrated the strongest predictive performance for CTRCD (AUC = 0.875; 95% CI: 0.735–1.000; p < 0.001). A cut-off value of ≥31.50 mg/dL provided 83.3% sensitivity and 87.5% specificity. Conclusions: Changes in apolipoprotein concentrations, particularly an increase in ApoC3 during anthracycline therapy, may be associated with the development of CTRCD. Assessment of ApoC3 and ApoE after chemotherapy may provide additional information for identifying breast cancer patients at higher risk of cardiac dysfunction.

Related

  1. Genetic Susceptibility to Anthracycline-Induced Cardiotoxicity in Australian Pediatric Cancer Patients
    Andreas Halman, Julia Netylko, Julian Stolper +7
    JACC: AdvancesPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMC
  2. Late Anthracycline Cardiotoxicity Mimicking Arrhythmogenic Cardiomyopathy in a Young Adult
    Maroun Chedid, Collin Barrett, Melanie Sun +2
    JACC Case ReportsPeer-reviewedCC BY-NC-ND 4.0Full text1 citedCardiovascular medicinePMCDOAJ
  3. Anthracycline Cardiotoxicity as Multicellular Network Failure: Cardiac Niche Reprogramming and Pathological Cell–Cell Communication
    Shuhui Wang, Quanquan Ding, Siyue Ding +2
    Journal of the American Heart AssociationPeer-reviewedCC BY-NC-NDCardiovascular medicineCrossref
  4. Exploring the protective mechanism of Huangqishengmaiyin against anthracycline-induced cardiotoxicity in breast cancer with concomitant gut microbiota modulation
    Yixuan Wang, Yeying Jin, Jiali Han +4
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicinePMCCrossrefEurope PMC
  5. Cardiotoxicity of Immune Checkpoint Inhibitors with Anthracycline Chemotherapy in Triple-Negative Breast Cancer.
    Nolan Holley, Syed Ahmad, Gary Monroe +4
    Current oncology (Toronto, Ont.)Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{puton2026dynamic,
  title = {{Dynamic Changes in Apolipoproteins During Anthracycline Therapy: An Exploratory Study of Potential Biomarkers of Cardiotoxicity in Breast Cancer Patients}},
  author = {Beata Puton and Agata Makówka and Anna Borowiec and Patrycja Ozdowska and Agnieszka Maria Żebrowska and Maciej Skrzypczak and Beata Kotowicz},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218250},
  url = {https://www.mdpi.com/2077-0383/15/21/8250},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Dynamic Changes in Apolipoproteins During Anthracycline Therapy: An Exploratory Study of Potential Biomarkers of Cardiotoxicity in Breast Cancer Patients
AU  - Beata Puton
AU  - Agata Makówka
AU  - Anna Borowiec
AU  - Patrycja Ozdowska
AU  - Agnieszka Maria Żebrowska
AU  - Maciej Skrzypczak
AU  - Beata Kotowicz
PY  - 2026
DA  - 2026/10/23
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218250
UR  - https://www.mdpi.com/2077-0383/15/21/8250
AB  - Background/Objectives: Cancer therapy-related cardiac dysfunction (CTRCD) is a clinically important complication of anthracycline-based chemotherapy, and early identification of patients at increased risk remains challenging. Apolipoproteins involved in lipid metabolism and inflammatory pathways may reflect cardiovascular alterations induced by anticancer treatment. This study aimed to evaluate changes in selected apolipoproteins and C-reactive protein (CRP) during anthracycline therapy and to assess their association with the development of CTRCD in patients with breast cancer. Methods: This prospective study included 54 patients with breast cancer treated with anthracycline-based chemotherapy at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Plasma concentrations of apolipoproteins A1, A2, B, C1, C3, D, E, H, and J, as well as CRP, were measured using an xMAP multiplex assay at baseline, after completion of chemotherapy, and approximately 6 months after treatment. Cardiac biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and NT-proBNP, were also assessed. CTRCD was diagnosed based on standard clinical and echocardiographic criteria. Results: Anthracycline therapy significantly affected the apolipoprotein profile, with decreased concentrations of apolipoproteins A1, A2, B, C1, E, H, and J, and increased concentrations of apolipoproteins C3 (ApoC3) and D and CRP during follow-up (all p < 0.001). Patients with CTRCD showed higher concentrations of selected apolipoproteins, particularly apolipoproteins C3, E (ApoE) and A2. The change in ApoC3 concentration from baseline to 6 months demonstrated the strongest predictive performance for CTRCD (AUC = 0.875; 95% CI: 0.735–1.000; p < 0.001). A cut-off value of ≥31.50 mg/dL provided 83.3% sensitivity and 87.5% specificity. Conclusions: Changes in apolipoprotein concentrations, particularly an increase in ApoC3 during anthracycline therapy, may be associated with the development of CTRCD. Assessment of ApoC3 and ApoE after chemotherapy may provide additional information for identifying breast cancer patients at higher risk of cardiac dysfunction.
SN  - 2077-0383
ER  -